TY  - JOUR
TI  - Association of CYP2D6*4 gene
polymorphism with early papillary thyroid
carcinoma
AB  - Objectives: CYP2D6 is highly polymorphic and a common
variant CYP2D6*4 results in the generation of poor metabolizer
enzyme. The CYP2D6*4 variant has been associated
with altered susceptibility to several cancers. The aim of
the present case-control study aims to investigate the
association between CYP2D6*4 polymorphism and the risk
of papillary thyroid carcinoma (PTC).
Materials and methods: Astudy population of 97 caseswith
PTC and 120 controls were included in the study. Genotyping
was done by polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method to detect the
presence of CYP2D6*4.
Results: The CYP2D6*4 was associated with significantly
increased PTC risk when compared with controls (odds ratio
[OR]=1.995, 95% confidence interval [CI]=1.060–3.752,
p=0.031). Besides, CYP2D6*4 allele frequency was higher in
PTC patients with age ≤50 years when compared to those
with age >50 (OR=2.380, 95% CI=1.191–4.755, p=0.013).
CYP2D6*4 allele frequency was higher in patients who had
encapsulated tumors, but it was not statistically significant
(p=0.111). No relationship was found between CYP2D6*4
and PTC variants or between early (I/II) and late (III/IV)
tumor stages.
Conclusions: Our findings indicate that the poor metabolizer
CYP2D6*4 genotype may be a risk factor, especially in
early PTC development. Further research with larger groups
is required for the confirmation of our consequences.
AU  - AKSOY, Figen
AU  - Ozturk, Tulin
AU  - İsbir, Turgay
AU  - Yilmaz Aydogan, Hulya
AU  - TEKER, Başak Akadam
AU  - Öztürk, Oğuz
AU  - Daglar Aday, Aynur
DO  - 10.1515/tjb-2020-0103
PY  - 2021
JO  - Türk Biyokimya Dergisi
VL  - 46
IS  - 4
SN  - 1303-829X
SP  - 455
EP  - 460
DB  - TRDizin
UR  - http://search/yayin/detay/524247
ER  -